Article thumbnail

Structural inferences for Cholera toxin mutations in Vibrio cholerae

By Gunasagaran Shamini, Manickam Ravichandran, John T Sinnott, Charurut Somboonwit, Harcharan S Sidhu, Paul Shapshak and Pandjassarame Kangueane

Abstract

Cholera is a global disease that has persisted for millennia. The cholera toxin (CT) from Vibrio cholerae is responsible for the clinical symptoms of cholera. This toxin is a hetero-hexamer (AB5) complex consisting of a subunit A (CTA) with a pentamer (B5) of subunit B (CTB). The importance of the AB5 complex for pathogenesis is established for the wild type O1 serogroup using known structural and functional data. However, its role is not yet documented in other known serogroups harboring sequence level residue mutations. The sequences for the toxin from different serogroups are available in GenBank (release 177). Sequence analysis reveals mutations at several sequence positions in the toxin across serogroups. Therefore, it is of interest to locate the position of these mutations in the AB5 structure to infer complex assembly for its functional role in different serogroups. We show that mutations in the CTA are at the solvent exposed regions of the AB5 complex, whereas those in the CTB are at the CTB/CTB interface of the homo-pentamer complex. Thus, the role of mutations at the CTB/CTB interface for B5 complex assembly is implied. It is observed that these mutations are often non-synonymous (e.g. polar to non-polar or vice versa). The formation of the AB5 complex involves inter-subunit residue-residue interactions at the protein-protein interfaces. Hence, these mutations, at the structurally relevant positions, are of importance for the understanding of pathogenesis by several serogroups. This is also of significance in the improvement of recombinant CT protein complex analogs for vaccine design and their use against multiple serogroups

Topics: Hypothesis
Publisher: Biomedical Informatics
OAI identifier: oai:pubmedcentral.nih.gov:3064844
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (1993). 90: 3750 [PMID:
  2. (2001). 98: 8536 [PMID: 11447291] Edited by VS Mathura Citation: Shamini et al.
  3. (2000). Appl Environ Microbiol.
  4. (1988). Cholera, the cholera enterotoxins, and the cholera enterotoxin-related enterotoxin family, In Owen P, Foster TS (Eds): Immuno-chemical and Molecular Genetic Analysis of Bacterial Pathogens.
  5. (1995). Clin Microbiol Rev.
  6. (2004). Colloids Surf B Biointerfaces.
  7. (2010). Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep.
  8. (2010). Disease Control and Prevention (CDC). Update: Cholera Outbreak -
  9. (2004). Emerg Infect Dis.
  10. (2006). Hyg Environ Health.
  11. (2003). Infect Immun.
  12. investors; United States patent US 6,149,919. 2000 Biocine S.p.A., assignee. Immunogenic detoxified mutants of cholera toxin and of the toxin LT, their preparation and their use for the preparation of vaccines.
  13. (2008). investors; United States patent US 7,361,355.
  14. (2004). Lancet
  15. (2010). Protein-protein interfaces in cholera toxin complex,
  16. Rappuoli VR, investors; United States patent US 7,632,513. 2009 Novartis Vaccines and Diagnostics SRL, assignee. Immunogenic detoxified mutants of cholera toxin.
  17. (1987). Rev Infect Dis.
  18. (2009). Wkly Epidemiol Rec.